U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2009
364
Substance Class Protein
Created
by admin
on Mon Mar 31 18:34:18 GMT 2025
Edited
by admin
on Mon Mar 31 18:34:18 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
91X1KLU43E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GOLIMUMAB
DASH   EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
SIMPONI
Preferred Name English
GOLIMUMAB [VANDF]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR .ALPHA.) (HUMAN MONOCLONAL CNTO 148 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CNTO 148 .KAPPA.-CHAIN), DIMER
Common Name English
GOLIMUMAB [JAN]
Common Name English
CNTO-148
Code English
golimumab [INN]
Common Name English
HUMAN ANTI-TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY
Common Name English
GOLIMUMAB [USAN]
Common Name English
CNTO 148
Code English
GOLIMUMAB [PURPLE BOOK CDER]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR .ALPHA.) (HUMAN MONOCLONAL CNTO 148 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL CNTO 148 .KAPPA.-CHAIN), DIMER
Common Name English
GOLIMUMAB [MI]
Common Name English
GOLIMUMAB [HSDB]
Common Name English
GOLIMUMAB [MART.]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR .ALPHA.) (HUMAN MONOCLONAL CNTO 148 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CNTO 148 .KAPPA.-CHAIN, DIMER
Common Name English
Golimumab [WHO-DD]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR .ALPHA.) (HUMAN MONOCLONAL CNTO 148 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL CNTO 148 .KAPPA.-CHAIN, DIMER
Common Name English
GOLIMUMAB [EMA EPAR]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548112
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
FDA ORPHAN DRUG 365112
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
WHO-ATC L04AB06
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
EMA ASSESSMENT REPORTS SIMPONI (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
FDA ORPHAN DRUG 368412
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
WHO-VATC QL04AB06
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
FDA ORPHAN DRUG 194204
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
EMA ASSESSMENT REPORTS SIMPONI (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
EMA ASSESSMENT REPORTS SIMPONI (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
NDF-RT N0000175610
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
FDA ORPHAN DRUG 159402
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
EMA ASSESSMENT REPORTS SIMPONI (AUTHORIZED: SPONDYLITIS, ANKYLOSING)
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
FDA ORPHAN DRUG 325610
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
Code System Code Type Description
HSDB
7852
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
CAS
476181-74-5
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
INN
8497
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201833
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
EVMPD
SUB25638
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
DAILYMED
91X1KLU43E
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
IUPHAR
6776
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
USAN
PP-88
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
NCI_THESAURUS
C87766
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
LACTMED
Golimumab
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
DRUG BANK
DB06674
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
MESH
C529000
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
SMS_ID
100000091704
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
RXCUI
819300
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
GOLIMUMAB
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
MERCK INDEX
m5830
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
4967
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
FDA UNII
91X1KLU43E
Created by admin on Mon Mar 31 18:34:18 GMT 2025 , Edited by admin on Mon Mar 31 18:34:18 GMT 2025
PRIMARY
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_306
N 2_306
Related Record Type Details
TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (MEMBRANE BOUND FORM)
TARGET -> INHIBITOR
TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (PLASMA DERIVED, SOLUBLE FORM)
TARGET -> INHIBITOR
Related Record Type Details
GOLIMUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966